ArticleBMC cancer2025
Exploring the clinical value of regional nodal irradiation in sentinel lymph node positive breast cancer patients omitting axillary dissection.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe practice of omitting of axillary lymph node dissection (ALND) in patients with a low tumor burden in sentinel lymph nodes (SLN) has become standard in managing early-stage breast cancer. This study aims to determine the clinical application value of regional lymph node irradiation (RNI) in such patients by analyzing relevant clinical and pathological data and survival outcomes.
methodsWe gathered data on 7603 patients from Shandong Cancer Hospital and Institutet between September 2014 and December 2022. Patients identified as SLN-positive who omitted ALND were classified based on whether RNI was included in their radiotherapy target area. Their case data and treatment details were analyzed, followed by regular follow-up assessments. The Kaplan-Meier method was used to compare recurrence and survival differences between the two groups. The primary outcome measured was locoregional recurrence-free survival (LRRFS), and the secondary outcomes were invasive disease-free survival (iDFS) and overall survival (OS).
resultsOut of 326 women, they were divided into the RNI group (n = 154) and no-RNI groups (n = 172). After a median follow-up of 47 months, the recurrence rate in the no-RNI group was 4.7%. Multivariate Cox proportional hazards analysis identified the triple-negative breast cancer (TNBC) subtype as a strong independent prognostic factor for iDFS (P < 0.001). Although RNI did not reach statistical significance in univariate analysis, it exhibited a significant protective effect after multivariate adjustment (P = 0.024). Kaplan-Meier survival analysis further revealed that RNI significantly improved LRRFS and iDFS (P = 0.042; P = 0.037, respectively), whereas no OS benefit was observed.
conclusionsAs the practice of surgical de-escalation becomes more widely adopted, the precise application of radiotherapy for SLN-positive patients exempt from ALND has become a key area of research. This study supports the use of RNI as crucial adjunctive treatment to enhance locoregional control, particularly for high-risk subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.